NeoGenomics (NASDAQ:NEO – Get Free Report) and RadNet (NASDAQ:RDNT – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.
Analyst Recommendations
This is a breakdown of recent ratings for NeoGenomics and RadNet, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeoGenomics | 1 | 3 | 8 | 0 | 2.58 |
| RadNet | 1 | 1 | 6 | 1 | 2.78 |
NeoGenomics presently has a consensus target price of $20.88, indicating a potential upside of 40.86%. RadNet has a consensus target price of $89.67, indicating a potential upside of 28.63%. Given NeoGenomics’ higher possible upside, research analysts clearly believe NeoGenomics is more favorable than RadNet.
Valuation & Earnings
This table compares NeoGenomics and RadNet”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeoGenomics | $727.33 million | 2.64 | -$108.03 million | ($0.25) | -59.28 |
| RadNet | $2.04 billion | 2.69 | -$18.65 million | ($0.29) | -240.38 |
RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NeoGenomics and RadNet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeoGenomics | -4.10% | -0.99% | -0.59% |
| RadNet | -0.94% | 3.14% | 1.08% |
Insider & Institutional Ownership
98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 77.9% of RadNet shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by insiders. Comparatively, 5.1% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
NeoGenomics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, RadNet has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Summary
RadNet beats NeoGenomics on 9 of the 15 factors compared between the two stocks.
About NeoGenomics
NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.
About RadNet
RadNet, Inc. operates outpatient diagnostic imaging centers in the United States. Its centers provide services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and nuclear medicine imaging. The company serves patients, physicians and healthcare organizations, with operations across several states, including California, Delaware, Florida, Maryland, New Jersey and New York. Its imaging centers offer diagnostic services for a range of medical needs, from routine screening to specialized examinations.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
